#1 Clinical Trials Search in Europe

Nicotinamide

Nicotinamide, also known as vitamin B3 or niacinamide, is being investigated in various clinical trials for its potential therapeutic effects across different medical conditions. This article explores the ongoing research into nicotinamide’s applications in treating diseases ranging from lupus and Alzheimer’s to sickle cell disease and COVID-19.

Table of Contents

What is Nicotinamide?

Nicotinamide, also known as niacinamide, is a form of vitamin B3. It’s an essential nutrient that plays a crucial role in various bodily functions[1]. Nicotinamide is involved in energy production, DNA repair, and maintaining healthy skin. It’s found naturally in foods and is also available as a dietary supplement.

Potential Uses of Nicotinamide

Research is ongoing to explore the potential benefits of nicotinamide in treating various conditions. Some of the areas being studied include:

  • Skin cancer prevention
  • Lupus (an autoimmune disease affecting various organs)
  • Neurodegenerative disorders (diseases that cause the brain and nerves to deteriorate)
  • Alzheimer’s disease
  • Friedreich’s ataxia (a genetic disorder affecting the nervous system)
  • COVID-19 related lymphopenia (low white blood cell count)
  • Lung cancer
  • Sickle cell disease

Nicotinamide for Skin Cancer Prevention

One of the most promising areas of research for nicotinamide is in the prevention of skin cancer, particularly in high-risk individuals. A study is being conducted to evaluate the effectiveness of nicotinamide in preventing keratinocyte carcinoma (a type of non-melanoma skin cancer) in organ transplant recipients[2]. These patients are at higher risk of skin cancer due to the long-term use of immunosuppressant drugs.

The study will involve 396 adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Participants will receive either nicotinamide (500 mg twice daily) or a placebo for up to 4 years. The researchers hope to determine if nicotinamide can safely reduce the rate of skin cancer in this high-risk population.

Nicotinamide in Lupus Treatment

Another area of research is the use of nicotinamide in treating lupus, particularly for skin lesions associated with the disease. A clinical study is testing the efficacy and safety of nicotinamide for lupus-associated skin lesions that haven’t responded well to standard treatments[1].

The study involves patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE). Participants will receive oral nicotinamide (500 mg twice daily) for 3 months, in addition to their current treatments. Researchers will assess changes in skin lesions, quality of life, and various immune system markers.

Nicotinamide in Neurodegenerative Disorders

Nicotinamide is being studied for its potential benefits in various neurodegenerative disorders. One such study is focusing on Friedreich’s ataxia, a genetic disorder that affects the nervous system and heart[3].

The research aims to determine if nicotinamide can increase the levels of a protein called frataxin, which is abnormally low in people with Friedreich’s ataxia. Participants will receive increasing doses of nicotinamide (from 2 to 8 grams per day) to find the optimal dose for increasing frataxin levels.

Other Conditions Being Studied

Nicotinamide is also being investigated for its potential benefits in several other conditions:

  • Alzheimer’s disease: A study is looking at whether nicotinamide can improve cognitive function in people with mild to moderate Alzheimer’s disease[4].
  • COVID-19: Researchers are studying if nicotinamide can help improve lymphocyte counts (a type of white blood cell) in patients with COVID-19[5].
  • Lung cancer: A trial is investigating whether nicotinamide can enhance the effects of standard treatments for certain types of lung cancer[6].
  • Sickle cell disease: A study is exploring the potential of nicotinamide, alone or in combination with other drugs, in treating sickle cell disease[7].

Dosage and Administration

The dosage of nicotinamide varies depending on the condition being treated and the specific study. Some examples include:

  • For skin cancer prevention: 500 mg twice daily[2]
  • For lupus-associated skin lesions: 500 mg twice daily[1]
  • For Friedreich’s ataxia: 2-8 grams daily[3]
  • For Alzheimer’s disease: 1500 mg twice daily[4]

It’s important to note that these dosages are being used in clinical trials and may not be appropriate for general use. Always consult with a healthcare provider before starting any new supplement regimen.

Safety and Side Effects

Nicotinamide is generally considered safe when used as directed. However, like any medication or supplement, it can cause side effects in some people. Possible side effects reported in studies include[6]:

  • Flushing and itching of the skin
  • Dizziness
  • Nausea
  • Epigastric discomfort (upper abdominal pain)
  • Loss of appetite
  • Elevated blood glucose
  • Elevated blood uric acid

Most studies are also monitoring for any potential effects on organ function, particularly in transplant recipients. It’s crucial to discuss the use of nicotinamide with your healthcare provider, especially if you have any pre-existing medical conditions or are taking other medications.

Condition Study Focus Dosage Key Outcomes Measured
Lupus Efficacy for skin lesions 500 mg twice daily Change in RCLASI score, quality of life
Alzheimer’s Disease Safety and efficacy 1500 mg twice daily Cognitive function, daily activities
Sickle Cell Disease Comparison with other treatments 1000 mg twice daily Blood hemoglobin levels
COVID-19 Effect on lymphopenia 500 mg daily (divided doses) Lymphocyte counts, mortality rate
Lung Cancer Anticancer activity 1 g daily Progression-free survival
Friedreich’s Ataxia Upregulation of Frataxin gene 2-8 grams (escalating) Frataxin levels, ataxia symptoms
Age-related Frailty Physical performance improvement 1.5 g daily Physical performance tests, biomarkers

FAQ

  • What is nicotinamide and how does it work? Nicotinamide is a form of vitamin B3. It acts as a precursor to NAD+, an essential coenzyme involved in cellular energy metabolism, DNA repair, and other crucial processes. As we age, NAD+ levels decrease, which may contribute to various age-related conditions.
  • What medical conditions are being studied with nicotinamide? Clinical trials are investigating nicotinamide for a wide range of conditions, including lupus, Alzheimer's disease, sickle cell disease, COVID-19, lung cancer, Friedreich's ataxia, and age-related frailty.
  • How is nicotinamide administered in these trials? Nicotinamide is typically administered orally in tablet form. Dosages vary depending on the study, ranging from 500 mg to 3 grams per day, often divided into multiple doses.
  • Are there any known side effects of nicotinamide? While generally considered safe, potential side effects of nicotinamide may include flushing, itching of the skin, nausea, headache, and in some cases, elevated blood glucose or uric acid levels. However, specific side effects are being monitored in each trial.
  • How long do these clinical trials typically last? The duration of nicotinamide trials varies widely, ranging from a few weeks to several months. Some studies, such as those for chronic conditions like Alzheimer's disease, may last up to 24 weeks or longer.

Ongoing Clinical Trials on Nicotinamide

  • Study on Faster Weaning from Ventilators in Critically Ill Patients Using Levosimendan and a Drug Combination

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Early Use of Levosimendan Compared to Placebo for Patients with Cardiogenic Shock

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Levosimendan for Patients with Cardiogenic Shock Being Weaned from ECMO

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study of controlled-release nicotinamide (CICR-NAM) tablets for treating mild to moderate ulcerative colitis

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effects and Safety of Nicotinamide for Patients with Type 2 Diabetes and Liver Fibrosis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A study to evaluate the effectiveness of nicotinamide in patients with Leber’s hereditary optic neuropathy who have experienced vision loss within the last 18 months

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Nicotinamide for Patients with Acute Kidney Injury

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Nicotinamide for Preventing Kidney Problems in Septic Shock Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effects of Nicotinamide for Patients with Dominant Optic Atrophy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • NAD+: Nicotinamide adenine dinucleotide, an essential coenzyme involved in cellular energy metabolism and other crucial processes.
  • Lupus erythematosus: An autoimmune disease that can affect various organs, often causing skin lesions and other symptoms.
  • EGFR mutation: A genetic alteration in the epidermal growth factor receptor, often associated with certain types of lung cancer.
  • Friedreich's ataxia: A rare genetic disorder affecting the nervous system and causing progressive damage to the spinal cord and nerves.
  • Sirtuin: A class of proteins involved in regulating cellular processes, including aging and transcription.
  • Epigenetic: Relating to changes in gene expression that do not involve alterations to the underlying DNA sequence.
  • Frataxin: A protein involved in iron metabolism, which is deficient in Friedreich's ataxia.
  • Lymphopenia: An abnormally low level of lymphocytes (a type of white blood cell) in the blood.
  • RCLASI: Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index, a measure of lupus-related skin lesion severity.
  • Posturography: A technique used to quantify postural control in standing positions, often used to assess balance disorders.

References

  1. https://clinicaltrials.gov/study/NCT03260166
  2. https://clinicaltrials.gov/study/NCT05955924
  3. https://clinicaltrials.gov/study/NCT01589809
  4. https://clinicaltrials.gov/study/NCT00580931
  5. https://clinicaltrials.gov/study/NCT04910230
  6. https://clinicaltrials.gov/study/NCT02416739
  7. https://clinicaltrials.gov/study/NCT04055818